Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients.
暂无分享，去创建一个
D. Doval | S. Nag | G. Bhattacharyya | Jun Li | D. Lokanatha | P. Scherle | P. Julka | T. Emm | S. Yeleswaram | S. Friedman | R. Levy | W. Garrett | S. Bondarde | T. Sahoo | K. Shenoy | R. Nagarkar | K. Kumar | S. Nag | P. Mohan | N. Narang | D. Raghunadharao | M. Walia | W. Yao | R. Newton | T. Sahoo | Tom Emm